Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Analyst target reached at $74.43 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: REDEMPLO.
Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform to silence disease-causing genes, with 18 clinical-stage drug candidates. It achieved its first commercial launch in 2025 with REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome.... Read more
Sell if holding. Analyst target reached at $74.43 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: REDEMPLO. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.6/10, moderate confidence.
Passes 4/6 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductREDEMPLO10-K Item 1A: 'Our prospects substantially depend on the success of our clinical-stage product candidates...or successfully commercialize REDEMPLO, our business could be materially harmed.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $74.43 — A.R:R is negative (-0.1) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Product: REDEMPLO. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $69.33. Score 5.6/10, moderate confidence.
Take-profit target: $74.95 (+0.5% upside). Prior stop was $69.33. Stop-loss: $69.33.
Concentration risk — Product: REDEMPLO; Analyst target reached - limited upside remaining; Near 52-week high (2.9% away).
Arrowhead Pharmaceuticals, Inc. trades at a P/E of 45.9 (forward -16.3). TrendMatrix value score: 3.3/10. Verdict: Sell.
19 analysts cover ARWR with a consensus score of 4.0/5. Average price target: $84.
What does Arrowhead Pharmaceuticals, Inc. do?Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform to silence disease-causing...
Arrowhead Pharmaceuticals develops RNAi therapeutics using its proprietary TRiM platform to silence disease-causing genes, with 18 clinical-stage drug candidates. It achieved its first commercial launch in 2025 with REDEMPLO (plozasiran) for Familial Chylomicronemia Syndrome. Multiple programs are licensed to partners including Sarepta, Amgen, Takeda, GSK, and Novartis.